Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Tahla MunirCarol MorenoCarolyn OwenGeorge FollowsOhad BenjaminiAnn JanssensMark-David LevinAnders OsterborgTadeusz RobakMartin SimkovicDon StevensSergey VoloshinVladimir VorobyevMunci YagciLoic YsebaertKeqin QiQianya QiLori ParisiSrimathi SrinivasanNatasha SchuierKurt BaetenAngela HowesDonne Bennett CacesCarsten Utoft NiemannArnon P KaterPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
), PFS rates remained high with ibrutinib + venetoclax; this is a novel finding and requires additional follow-up to confirm its persistence over time.